SEA CD70
Alternative Names: PF-08046040; SEA-CD70Latest Information Update: 28 Jun 2025
At a glance
- Originator Seattle Genetics
- Developer BeOne Medicines; Seagen
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia in China (IV, Infusion)
- 28 Jun 2025 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in Netherlands (IV, Infusion)
- 28 Jun 2025 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in USA (IV, Infusion)